Loading...
•
Sep 30, 2025
Akebia Q3 2025 Earnings Report
Estimated Revenue:$48.3M
+6.5% YoY
Estimated EPS:-$0.02
+67.5% YoY
Key Takeaways
Akebia achieved net income of $540,000 in Q3 2025, reversing a loss from the prior year, as total revenue rose to $58.8 million, supported by strong uptake of Vafseo and sustained Auryxia performance.
Total revenue rose to $58.8M, up from $37.4M in Q3 2024.
Net income reached $540K, compared to a $20M loss a year earlier.
Vafseo net product revenue totaled $14.3M in its first U.S. launch year.
Prescriber base for Vafseo grew to approximately 725, with 85% of prescriptions being refills.
Revenue by Segment
Forward Guidance
Akebia expects broader uptake of Vafseo driven by increased patient access and DaVita pilot completion, with a pathway to profitability under its current operating plan.
Positive Outlook
- Vafseo access expected to expand to 275,000 patients by year-end
- DaVita operational pilot expected to complete in Q4 2025
- Strong uptake at USRC with over 85% of physicians prescribing Vafseo
- Post-hoc data shows Vafseo has favorable outcomes vs. ESAs
- Akebia believes it is financed to achieve profitability
Challenges Ahead
- No alignment with FDA on Phase 3 trial for non-dialysis patients
- Akebia does not plan to initiate VALOR trial
- No plans to pursue broader label for Vafseo in non-dialysis CKD
- Increased R&D and SG&A expenses in Q3 2025
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...